Tuesday, February 27, 2018

Amgen Ventures Backs Senti Biosciences In $53M Funding

Amgen Ventures, the venture capital arm of Amgen, is one of the investors in synthetic biology startup Senti Biosciences. Senti said on Tuesday that it has raised $53M in a funding round. The funding round led by New Enterprise Associates, and also included 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital. Senti Biosciences is based in San Francisco. More information »